New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2014
07:24 EDTXXII22nd Century files for NYSE MKT listing, NASDAQ Capital Market listing
22nd Century announced that the company submitted documentation to the New York Stock Exchange and answered questions pursuant to an initial request letter as a first step toward filing a formal application for listing its common shares on NYSE MKT. The formal application will be submitted immediately after a committee at the NYSE reviews 22nd Century Group and issues a clearance letter for the company to proceed. The committee review is scheduled for February 20. The company believes it currently meets all eligibility requirements of NYSE MKT. 22nd Century Group also sent an application to NASDAQ for listing its common shares on The NASDAQ Capital Market. NASDAQ has put the application on hold until the company’s share price meets the minimum requirements of the exchange. With the exception of the minimum share price requirement, 22nd Century Group believes it currently meets all other eligibility requirements of The NASDAQ Capital Market. Upon the company’s share price achieving the minimum requirements, 22nd Century Group’s application will move forward.
News For XXII From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
13:45 EDTXXII22nd Century to participate in a conference call hosted by Wells Fargo
Wells Fargo Tobacco Analyst Herzog hosts CEO Pandolfino on a "Tobacco Talk" conference call to be held on September 30 at 11 am.
September 25, 2014
07:25 EDTXXII22nd Century granted meeting with FDA for cigarette development
22nd Century Group announced that the Center for Tobacco Products of the U.S. Food and Drug Administration has granted the company a meeting on November 12 to discuss the further development of the company’s potential modified risk tobacco product, code-named BRAND B, or BB-1, which is a cigarette that is designed to provide an exceptionally low tar-to-nicotine yield ratio. As compared to other commercial low-yield cigarettes, the only differentiating factor of the BB-1 cigarette is that 22nd Century’s high-nicotine tobacco is used, which tobacco is planted, grown, harvested, cured, and processed in exactly the same manner as conventional commercial tobacco. The company intends to demonstrate evidence that 22nd Century’s cigarettes reduce exposure to tobacco toxins and are likely to result in a reduction in morbidity or mortality among individual tobacco users. The purpose of the company’s meeting with CTP will be to seek the Agency’s concurrence that 22nd Century’s proposed BB-1 clinical study is adequate to support the development of BB-1 as a potential modified risk tobacco product. With FDA concurrence, 22nd Century will conduct an exposure study on BB-1 in 1Q15.
September 18, 2014
08:59 EDTXXIIOn The Fly: Pre-market Movers
Subscribe for More Information
08:11 EDTXXII22nd Century announces worldwide license agreement with Anandia
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use